指南与共识贫血与红细胞疾病血栓与止血

成人埃文斯综合征的诊断与管理:首部共识推荐

Diagnosis and management of Evans syndrome in adults: first consensus recommendations.
指南 / 共识 · Lancet Haematol · 2024-07-02

埃文斯综合征是一种罕见病,临床病程严重、复发率高、感染和血栓并发症多,有时致命,管理高度异质。本文报告首部基于共识的专家推荐,采用模糊德尔菲法,由来自五个国家的13名国际专家对42项问卷进行两轮7分制评分,旨在统一成人埃文斯综合征的诊断与管理。

要点

  • 推荐广泛的临床和实验室诊断检查,包括骨髓评估和CT扫描。
  • 推荐积极的一线治疗:泼尼松(联合或不联合静脉注射免疫球蛋白),免疫性血小板减少症与自身免疫性溶血性贫血的疗程和减量方案不同。
  • 利妥昔单抗强烈推荐用于冷型自身免疫性溶血性贫血的一线治疗,以及温型自身免疫性溶血性贫血和特定免疫性血小板减少症患者的二线治疗。

核心结论

  • 这些基于共识的推荐应促进临床实践中埃文斯综合征诊断和管理的最佳实践。

研究设计与样本

  • 首部基于共识的专家推荐,采用模糊德尔菲共识方法,由来自五个国家的13名国际专家组成的小组对42项问卷进行两轮评分,使用7点李克特量表,于2023年全年以虚拟方式会议。

主要发现

  • 专家小组推荐广泛的临床和实验室诊断检查,包括骨髓评估和CT扫描。
  • 推荐积极的一线治疗:泼尼松(联合或不联合静脉注射免疫球蛋白),免疫性血小板减少症和自身免疫性溶血性贫血的疗程和减量方案不同。
  • 利妥昔单抗强烈推荐用于冷型自身免疫性溶血性贫血的一线治疗,以及温型自身免疫性溶血性贫血和伴有抗磷脂抗体、既往血栓事件或相关淋巴增殖性疾病的免疫性血小板减少症患者的二线治疗。
  • 利妥昔单抗不推荐用于免疫缺陷或严重感染患者,脾切除术同样不推荐。
  • 血小板生成素受体激动剂推荐用于慢性免疫性血小板减少症和既往4级感染的情况;福坦替尼推荐作为三线或更后线治疗,建议作为既往血栓事件患者的二线治疗。

关键数值与推荐

  • 利妥昔单抗:强烈推荐用于冷型自身免疫性溶血性贫血的一线治疗;强烈推荐用于温型自身免疫性溶血性贫血和伴有抗磷脂抗体、既往血栓事件或相关淋巴增殖性疾病的免疫性血小板减少症患者的二线治疗。
  • 利妥昔单抗:不推荐用于免疫缺陷或严重感染患者;脾切除术同样不推荐。
  • 血小板生成素受体激动剂:推荐用于慢性免疫性血小板减少症和既往4级感染的情况。
  • 福坦替尼:推荐作为三线或更后线治疗;建议作为既往血栓事件患者的二线治疗。
  • 免疫抑制剂:已移至三线或更后线治疗。

临床怎么用

  • 推荐在网织红细胞计数不足的自身免疫性溶血性贫血中使用重组促红细胞生成素。
  • 推荐在复发性冷型自身免疫性溶血性贫血中使用补体抑制剂舒替利单抗。
  • 推荐在继发于淋巴增殖性疾病的埃文斯综合征中使用利妥昔单抗联合苯达莫司汀。
  • 给出了支持治疗、血小板或红细胞输注以及血栓和抗生素预防的推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evans syndrome is a rare disease marked by a severe clinical course, high relapse rate, infectious and thrombotic complications, and sometimes fatal outcome. Management is highly heterogeneous. There are several case reports but few large retrospective studies and no prospective or randomised trials. Here, we report the results of the first consensus-based expert recommendations aimed at harmonising the diagnosis and management of Evans syndrome in adults. After reviewing the literature, we used a fuzzy Delphi consensus method, with two rounds of a 42-item questionnaire that were scored by a panel of 13 international experts from five countries using a 7-point Likert scale. Panellists were selected by the core panel on the basis of their personal experience and previous publications on Evans syndrome and immune cytopenias; they met virtually throughout 2023. The panellists recommended extensive clinical and laboratory diagnostic tests, including bone marrow evaluation and CT scan, and an aggressive front-line therapy with prednisone (with or without intravenous immunoglobulins), with different treatment durations and tapering for immune thrombocytopenia and autoimmune haemolytic anaemias (AIHAs). Rituximab was strongly recommended as first-line treatment in cold-type AIHA and as second-line treatment in warm-type AIHA and patients with immune thrombocytopenia and antiphospholipid antibodies, previous thrombotic events, or associated lymphoproliferative diseases. However, rituximab was discouraged for patients with immunodeficiency or severe infections, with the same applying to splenectomy. Thrombopoietin receptor agonists were recommended for chronic immune thrombocytopenia and in the case of previous grade 4 infection. Fostamatinib was recommended as third-line or further-line treatment and suggested as second-line therapy for patients with previous thrombotic events. Immunosuppressive agents have been moved to third-line or further-line treatment. The panellists recommended the use of recombinant erythropoietin in AIHA in the case of inadequate reticulocyte counts, use of the complement inhibitor sutimlimab for relapsed cold AIHA, and the combination of rituximab plus bendamustine in Evans syndrome secondary to lymphoproliferative disorders. Finally, recommendations were given for supportive therapy, platelet or red blood cell transfusions, and thrombotic and antibiotic prophylaxis. These consensus-based recommendations should facilitate best practice for diagnosis and management of Evans syndrome in clinical practice.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Fattizzo B, Marchetti M, Michel M, et al. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol. 2024. PMID: 38968944. doi:10.1016/S2352-3026(24)00144-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。